新型碳青霉烯类药物RS-533对需氧和厌氧革兰氏阳性及革兰氏阴性菌的体外活性及β-内酰胺酶稳定性
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.
作者信息
Neu H C, Chin N X, Saha G, Labthavikul P
出版信息
Antimicrob Agents Chemother. 1986 Dec;30(6):828-34. doi: 10.1128/AAC.30.6.828.
Abstract
RS-533 is a novel carbapenem antibiotic. Its activity was compared with that of imipenem and the new cephalosporins, aztreonam, piperacillin, and tobramycin. RS-533 had activity comparable to that of imipenem, inhibiting the majority of the Enterobacteriaceae, streptococci, staphylococci, and Bacteroides species at concentrations of less than or equal to 2 micrograms/ml. RS-533 inhibited Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens resistant to ceftazidime, aztreonam, and cefoperazone, but RS-533 did not inhibit all methicillin-resistant Staphylococcus aureus or Pseudomonas maltophilia. It inhibited tobramycin-resistant members of the Enterobacteriaceae and Pseudomonas aeruginosa. RS-533 was stable against attack by common chromosomal and plasmid-mediated beta-lactamases and was an effective inhibitor of many beta-lactamases.
摘要
RS - 533是一种新型碳青霉烯类抗生素。将其活性与亚胺培南以及新型头孢菌素、氨曲南、哌拉西林和妥布霉素的活性进行了比较。RS - 533的活性与亚胺培南相当，在浓度小于或等于2微克/毫升时能抑制大多数肠杆菌科细菌、链球菌、葡萄球菌和拟杆菌属菌种。RS - 533能抑制对头孢他啶、氨曲南和头孢哌酮耐药的阴沟肠杆菌、弗氏柠檬酸杆菌和粘质沙雷氏菌，但RS - 533不能抑制所有耐甲氧西林金黄色葡萄球菌或嗜麦芽窄食单胞菌。它能抑制肠杆菌科细菌和铜绿假单胞菌中对妥布霉素耐药的菌株。RS - 533对常见染色体介导和质粒介导的β - 内酰胺酶具有稳定性，并且是许多β - 内酰胺酶的有效抑制剂。
相似文献
1
In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.新型碳青霉烯类药物RS-533对需氧和厌氧革兰氏阳性及革兰氏阴性菌的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1986 Dec;30(6):828-34. doi: 10.1128/AAC.30.6.828.
2
The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.新型广谱β-内酰胺酶稳定头孢菌素BMY 28142的活性。
J Antimicrob Chemother. 1986 Apr;17(4):441-52. doi: 10.1093/jac/17.4.441.
3
In vitro activity and beta-lactamase stability of LJC 10,627.LJC 10,627的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1992 Jul;36(7):1418-23. doi: 10.1128/AAC.36.7.1418.
4
The in-vitro activity and beta-lactamase stability of carumonam.卡芦莫南的体外活性及β-内酰胺酶稳定性
J Antimicrob Chemother. 1986 Jul;18(1):35-44. doi: 10.1093/jac/18.1.35.
5
In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):908-16. doi: 10.1007/BF01963782.
6
In vitro activity of a new cephalosporin ME-1206 compared with other agents.新型头孢菌素ME-1206与其他药物的体外活性比较。
Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):417-24. doi: 10.1016/0732-8893(91)90068-q.
7
Comparative in vitro activity and beta-lactamase stability of CGP 31523A, a new aminothiazolyl cephalosporin.
Chemioterapia. 1986 Apr;5(2):92-100.
8
9
In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338.新型碳青霉烯类药物SM-7338的体外活性及β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1989 Jul;33(7):1009-18. doi: 10.1128/AAC.33.7.1009.
10
Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.氨曲南：抗菌活性、β-内酰胺酶稳定性以及纸片扩散法药敏试验的解释标准和质量控制指南
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S594-604. doi: 10.1093/clinids/7.supplement_4.s594.
引用本文的文献
1
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae.新型口服碳青霉烯类抗生素替比培南对青霉素不敏感肺炎链球菌的体外活性
Antimicrob Agents Chemother. 2005 Mar;49(3):889-94. doi: 10.1128/AAC.49.3.889-894.2005.
2
Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002.1999年至2002年日本脑膜炎链球菌菌株的抗生素敏感性与青霉素结合蛋白基因及血清型分布的关系
Antimicrob Agents Chemother. 2004 May;48(5):1488-94. doi: 10.1128/AAC.48.5.1488-1494.2004.
3
New insertion sequence elements in the upstream region of cfiA in imipenem-resistant Bacteroides fragilis strains.耐亚胺培南脆弱拟杆菌菌株中cfiA上游区域的新插入序列元件
Antimicrob Agents Chemother. 2003 Mar;47(3):979-85. doi: 10.1128/AAC.47.3.979-985.2003.
4
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.口服β-内酰胺类药物法罗培南对美国近期分离出的肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的活性。
Antimicrob Agents Chemother. 2002 Feb;46(2):550-5. doi: 10.1128/AAC.46.2.550-555.2002.
5
Comparative pharmacokinetics of the carbapenems: clinical implications.碳青霉烯类药物的比较药代动力学：临床意义。
Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002.
6
In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.LJC 11,036的体外抗菌活性，LJC 11,036是L-084的一种活性代谢产物，L-084是一种新型口服碳青霉烯类抗生素，具有强大的抗肺炎球菌活性。
Antimicrob Agents Chemother. 1999 Aug;43(8):2010-6. doi: 10.1128/AAC.43.8.2010.
7
In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem.新型口服碳青霉烯类药物CS-834的体外和体内抗菌活性
Antimicrob Agents Chemother. 1997 Dec;41(12):2652-63. doi: 10.1128/AAC.41.12.2652.
8
Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane.碳青霉烯类药物帕尼培南的活性以及OprD（D2）蛋白在其通过铜绿假单胞菌外膜扩散中的作用。
Antimicrob Agents Chemother. 1993 Feb;37(2):322-7. doi: 10.1128/AAC.37.2.322.
9
In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity.新型碳青霉烯类抗生素BO-2727的体外活性，其具有强大的抗假单胞菌活性。
Antimicrob Agents Chemother. 1993 Dec;37(12):2756-9. doi: 10.1128/AAC.37.12.2756.
10
Transient carbapenem resistance induced by salicylate in Pseudomonas aeruginosa associated with suppression of outer membrane protein D2 synthesis.
Antimicrob Agents Chemother. 1993 Dec;37(12):2743-6. doi: 10.1128/AAC.37.12.2743.
本文引用的文献
1
Method of reliable determination of minimal lethal antibiotic concentrations.可靠测定最低致死抗生素浓度的方法。
Antimicrob Agents Chemother. 1980 Nov;18(5):699-708. doi: 10.1128/AAC.18.5.699.
2
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.N-甲酰亚胺硫霉素对革兰氏阳性和革兰氏阴性需氧及厌氧菌的体外比较活性及其β-内酰胺酶稳定性
Antimicrob Agents Chemother. 1982 Jan;21(1):180-7. doi: 10.1128/AAC.21.1.180.
3
The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.半合成硫霉素衍生物MK0787及其对一系列来自临床相关细菌物种的β-内酰胺酶的特性。
J Antimicrob Chemother. 1981 Mar;7(3):279-85. doi: 10.1093/jac/7.3.279.
4
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.新型青霉烯类抗生素FCE 22101与其他β-内酰胺类抗生素的体外活性比较。
Antimicrob Agents Chemother. 1983 Dec;24(6):909-14. doi: 10.1128/AAC.24.6.909.
5
Susceptibility of anaerobic bacteria to imipenem.厌氧菌对亚胺培南的敏感性。
J Antimicrob Chemother. 1983 Dec;12 Suppl D:47-51. doi: 10.1093/jac/12.suppl_d.47.
6
Monoclonal antibodies of hybridomas.杂交瘤的单克隆抗体。
Rev Infect Dis. 1983 Jan-Feb;5(1):9-34. doi: 10.1093/clinids/5.1.9.
7
Review of the in vitro spectrum of activity of imipenem.亚胺培南体外活性谱的综述。
Am J Med. 1985 Jun 7;78(6A):22-32. doi: 10.1016/0002-9343(85)90098-1.
8
Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.碳青霉烯类，一类新型β-内酰胺抗生素。亚胺培南/西司他丁的发现与研发。
Am J Med. 1985 Jun 7;78(6A):3-21. doi: 10.1016/0002-9343(85)90097-x.
Zotero 插件